Johnson & Johnson (JNJ)vsPro-Dex Inc (PDEX)
JNJ
Johnson & Johnson
$271.17
+0.86%
HEALTHCARE · Cap: $615.87B
PDEX
Pro-Dex Inc
$63.19
+1.48%
HEALTHCARE · Cap: $201.17M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 127995% more annual revenue ($99.33B vs $77.55M). PDEX leads profitability with a 17.6% profit margin vs 16.2%. PDEX trades at a lower P/E of 15.1x. PDEX earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy57
out of 100
Grade: C
PDEX
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$271.17
$127.05 premium
Intrinsic value data unavailable for PDEX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Earnings expanding 143.4% YoY
Safe zone — low bankruptcy risk
Every $100 of equity generates 27 in profit
Attractively priced relative to earnings
16.6% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : PDEX
The strongest argument for PDEX centers on EPS Growth, Altman Z-Score, Return on Equity. Profitability is solid with margins at 17.6% and operating margin at 17.3%. Revenue growth of 16.6% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : PDEX
The primary concerns for PDEX are Market Cap, Free Cash Flow.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PDEX is a growth play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.21 — expect wider price swings.
PDEX is growing revenue faster at 16.6% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
PDEX scores higher overall (59/100 vs 57/100), backed by strong 17.6% margins and 16.6% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Pro-Dex Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company is headquartered in Irvine, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?